These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 21391146)
1. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors. Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors. Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015 [TBL] [Abstract][Full Text] [Related]
3. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors. Kansal N; Silakari O; Ravikumar M Eur J Med Chem; 2010 Jan; 45(1):393-404. PubMed ID: 19892442 [TBL] [Abstract][Full Text] [Related]
4. Pharmacophore modeling and virtual screening to identify potential RET kinase inhibitors. Shih KC; Shiau CW; Chen TS; Ko CH; Lin CL; Lin CY; Hwang CS; Tang CY; Chen WR; Huang JW Bioorg Med Chem Lett; 2011 Aug; 21(15):4490-7. PubMed ID: 21724393 [TBL] [Abstract][Full Text] [Related]
5. Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach. Parenti MD; Pacchioni S; Ferrari AM; Rastelli G J Med Chem; 2004 Aug; 47(17):4258-67. PubMed ID: 15293997 [TBL] [Abstract][Full Text] [Related]
6. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Yu H; Wang Z; Zhang L; Zhang J; Huang Q Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906 [TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors. Wang HY; Cao ZX; Li LL; Jiang PD; Zhao YL; Luo SD; Yang L; Wei YQ; Yang SY Bioorg Med Chem Lett; 2008 Sep; 18(18):4972-7. PubMed ID: 18762425 [TBL] [Abstract][Full Text] [Related]
8. Design checkpoint kinase 2 inhibitors by pharmacophore modeling and virtual screening techniques. Wang YL; Lin CY; Shih KC; Huang JW; Tang CY Bioorg Med Chem Lett; 2013 Dec; 23(23):6286-91. PubMed ID: 24144850 [TBL] [Abstract][Full Text] [Related]
9. A specific pharmacophore model of Aurora B kinase inhibitors and virtual screening studies based on it. Wang HY; Li LL; Cao ZX; Luo SD; Wei YQ; Yang SY Chem Biol Drug Des; 2009 Jan; 73(1):115-26. PubMed ID: 19152640 [TBL] [Abstract][Full Text] [Related]
10. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. Charrier JD; Miller A; Kay DP; Brenchley G; Twin HC; Collier PN; Ramaya S; Keily SB; Durrant SJ; Knegtel RM; Tanner AJ; Brown K; Curnock AP; Jimenez JM J Med Chem; 2011 Apr; 54(7):2341-50. PubMed ID: 21391610 [TBL] [Abstract][Full Text] [Related]
11. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation. Bavi R; Kumar R; Choi L; Woo Lee K PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025 [TBL] [Abstract][Full Text] [Related]
12. Pharmacophore identification, docking and "in silico" screening for novel CDK1 inhibitors. Dong X; Yan J; Du L; Wu P; Huang S; Liu T; Hu Y J Mol Graph Model; 2012 Jul; 37():77-86. PubMed ID: 22622012 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking. Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639 [TBL] [Abstract][Full Text] [Related]
14. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418 [TBL] [Abstract][Full Text] [Related]
15. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors. Saxena S; Chaudhaery SS; Varshney K; Saxena AK SAR QSAR Environ Res; 2010 Jul; 21(5-6):445-62. PubMed ID: 20818581 [TBL] [Abstract][Full Text] [Related]
16. Virtual screening for Raf-1 kinase inhibitors based on pharmacophore model of substituted ureas. Li HF; Lu T; Zhu T; Jiang YJ; Rao SS; Hu LY; Xin BT; Chen YD Eur J Med Chem; 2009 Mar; 44(3):1240-9. PubMed ID: 18947905 [TBL] [Abstract][Full Text] [Related]
17. Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches. Meganathan C; Sakkiah S; Lee Y; Narayanan JV; Lee KW J Mol Model; 2013 Feb; 19(2):715-26. PubMed ID: 23015102 [TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors. Gupta AK; Bhunia SS; Balaramnavar VM; Saxena AK SAR QSAR Environ Res; 2011 Jun; 22(3):239-63. PubMed ID: 21400356 [TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543 [TBL] [Abstract][Full Text] [Related]